I need the advice of an Independent Expert

In the Scheme booklet Deloittes initially reject the use of DCF

we do not consider it appropriate to adopt the discounted cash flow methodology as our primary valuation approach.

then subsequently use DCF

To provide additional evidence of the fair market value of a share in the Cellestis, we have considered the value of a share using a high level discounted cash flow methodology

When CSAG use DCF it is "inappropriate" yet when Deloittes use DCF it becomes "additional evidence."